A Phase II Study to Investigate a Combination of Metformin With Chemo-Radiotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer
ALMERA is a randomized, phase II, open label study in patients with locally advanced
non-small cell lung cancer (NSCLC) which will compare standard radiation therapy plus concurrent
chemotherapy with or without consolidation versus the same treatment plus concurrent
Metformin continuing for 12 months. Metformin is a well tolerated and inexpensive drug that
has the potential to improve cancer patient outcomes.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society